CN1260778A - 前列腺素药用组合物 - Google Patents

前列腺素药用组合物 Download PDF

Info

Publication number
CN1260778A
CN1260778A CN98806194A CN98806194A CN1260778A CN 1260778 A CN1260778 A CN 1260778A CN 98806194 A CN98806194 A CN 98806194A CN 98806194 A CN98806194 A CN 98806194A CN 1260778 A CN1260778 A CN 1260778A
Authority
CN
China
Prior art keywords
residue
formula
group
abaprost
equal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98806194A
Other languages
English (en)
Chinese (zh)
Inventor
P·德尔索达托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA filed Critical Nicox SA
Publication of CN1260778A publication Critical patent/CN1260778A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
CN98806194A 1997-06-19 1998-06-17 前列腺素药用组合物 Pending CN1260778A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI97A001440 1997-06-19
IT97MI001440A IT1292377B1 (it) 1997-06-19 1997-06-19 Composizioni farmaceutiche a base di prostaglandine

Publications (1)

Publication Number Publication Date
CN1260778A true CN1260778A (zh) 2000-07-19

Family

ID=11377397

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98806194A Pending CN1260778A (zh) 1997-06-19 1998-06-17 前列腺素药用组合物

Country Status (19)

Country Link
US (1) US6211233B1 (enExample)
EP (1) EP0989972B1 (enExample)
JP (1) JP4394170B2 (enExample)
KR (1) KR20010013625A (enExample)
CN (1) CN1260778A (enExample)
AT (1) ATE225771T1 (enExample)
AU (1) AU740683B2 (enExample)
BR (1) BR9810163B1 (enExample)
CA (1) CA2292836C (enExample)
DE (1) DE69808619T2 (enExample)
DK (1) DK0989972T3 (enExample)
ES (1) ES2185188T3 (enExample)
HU (1) HUP0004071A3 (enExample)
IL (1) IL132690A (enExample)
IT (1) IT1292377B1 (enExample)
PT (1) PT989972E (enExample)
RU (1) RU2000100807A (enExample)
SI (1) SI0989972T1 (enExample)
WO (1) WO1998058910A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100469765C (zh) * 2004-01-05 2009-03-18 尼考斯股份公司 前列腺素硝基氧衍生物
CN113943266A (zh) * 2021-11-18 2022-01-18 广州楷石医药有限公司 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途
CN116178233A (zh) * 2023-02-27 2023-05-30 广州楷石生物科技有限公司 伊洛前列素一氧化氮供体药物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
IT1311923B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1319201B1 (it) * 2000-10-12 2003-09-26 Nicox Sa Farmaci per il diabete.
AU2002243795A1 (en) * 2001-01-30 2002-08-12 Pharmaceutical Research Corporation Use of prostaglandin analogs for treatment of cardiac conditions
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
CA2475209A1 (en) * 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
WO2007000642A1 (en) * 2005-06-29 2007-01-04 Pfizer Inc. Fluoroprostaglandins nitroderivatives
WO2007000641A2 (en) * 2005-06-29 2007-01-04 Pfizer Inc. Prostaglandin derivatives
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
AU2007243765A1 (en) * 2006-03-29 2007-11-08 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8041859B2 (en) * 2007-11-05 2011-10-18 Honywell International Inc. Apparatus and method for connectivity in networks capable of non-disruptively disconnecting peripheral devices
WO2012145520A2 (en) 2011-04-19 2012-10-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
US9844599B2 (en) 2013-01-21 2017-12-19 Apparao Satyam Nitric oxide releasing produgs of therapeutic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3371199D1 (en) * 1982-08-24 1987-06-04 Teijin Ltd Novel 6-nitroprostaglandin derivatives, process for production thereof, and use thereof
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
IT1243367B (it) 1990-07-26 1994-06-10 Italfarmaco Spa Derivati acidi benzoici sostituiti ad attivita' cardiovascolare
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5328933A (en) 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
AU702662B2 (en) 1994-05-10 1999-02-25 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
US5625083A (en) * 1995-06-02 1997-04-29 Bezuglov; Vladimir V. Dinitroglycerol esters of unsaturated fatty acids and prostaglandins

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100469765C (zh) * 2004-01-05 2009-03-18 尼考斯股份公司 前列腺素硝基氧衍生物
CN113943266A (zh) * 2021-11-18 2022-01-18 广州楷石医药有限公司 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途
WO2023088497A3 (zh) * 2021-11-18 2023-07-20 广州楷石医药有限公司 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途
CN119350280A (zh) * 2021-11-18 2025-01-24 广州楷石医药有限公司 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途
CN116178233A (zh) * 2023-02-27 2023-05-30 广州楷石生物科技有限公司 伊洛前列素一氧化氮供体药物

Also Published As

Publication number Publication date
KR20010013625A (ko) 2001-02-26
BR9810163B1 (pt) 2009-01-13
US6211233B1 (en) 2001-04-03
WO1998058910A1 (en) 1998-12-30
PT989972E (pt) 2003-02-28
RU2000100807A (ru) 2002-02-27
DE69808619T2 (de) 2003-06-12
AU8438698A (en) 1999-01-04
JP4394170B2 (ja) 2010-01-06
IL132690A (en) 2004-06-01
CA2292836A1 (en) 1998-12-30
ATE225771T1 (de) 2002-10-15
EP0989972B1 (en) 2002-10-09
HUP0004071A3 (en) 2002-12-28
DK0989972T3 (da) 2003-02-10
HUP0004071A2 (hu) 2001-04-28
AU740683B2 (en) 2001-11-08
ES2185188T3 (es) 2003-04-16
IL132690A0 (en) 2001-03-19
JP2002506440A (ja) 2002-02-26
ITMI971440A1 (it) 1998-12-19
DE69808619D1 (de) 2002-11-14
SI0989972T1 (en) 2003-04-30
BR9810163A (pt) 2000-08-08
ITMI971440A0 (enExample) 1997-06-19
EP0989972A1 (en) 2000-04-05
CA2292836C (en) 2010-03-02
IT1292377B1 (it) 1999-02-08

Similar Documents

Publication Publication Date Title
CN1260778A (zh) 前列腺素药用组合物
CN100335049C (zh) 泻药组合物
CN1126466A (zh) 二硫化物
CN1145619C (zh) 1,4-苯并硫杂吖庚因衍生物、其制备方法、含有该化合物的药物及其用途
CN1269785A (zh) 用作fp激活剂的芳香族c16－c20－取代四氢前列腺素
CN1283123A (zh) 缓释药物组合物
CN1155276A (zh) 酶抑制剂
CN1264820C (zh) 降眼压类脂类
CN1527823A (zh) 经氘代的3－哌啶子基苯基·乙基酮以及含化合物的药物组合物
CN1144588C (zh) 睡眠诱发剂
CN1273140C (zh) 导泻组合物
CN1206997C (zh) 内皮缩血管肽拮抗剂
CN1638756A (zh) 左旋(r)班布特罗及其药物用途
CN1071833A (zh) N-苯基-2氰代-3-羟基巴豆酰胺衍生物及其作为免疫调节药物的用途
JP2002534389A (ja) 女性性機能障害の治療のための方法および組成物
CN1382046A (zh) 15－羟基二十碳四烯酸的插入杂原子的类似物和使用方法
CN1198735A (zh) 苯磺酰胺衍生物以及它们的制备和在医领域中的应用
CN1867310A (zh) 促进毛发生长的组合物和方法
JPWO2008093655A1 (ja) ポリアルコール化合物および医薬
CN1224626C (zh) β－D－5－硫代木糖衍生物、其制备方法及医疗用途
US5516796A (en) Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
CN1107333A (zh) 那布扶林镇痛剂的长效前体药物及其制备方法
CN1202826C (zh) 神经障碍治疗剂
JP5536456B2 (ja) アデノシン受容体へ作用する新規アミド
WO2020142865A1 (zh) 一种苯甲酰胺类化合物、中间体、制备方法及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned